BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Intrac Inc. (ITRD.OB) And Innovative Drug Delivery Systems, Inc. (IDDS) Release: Pivotal Phase II/III Study Shows Dyloject(TM) Significantly Reduces Moderate-To-Severe Post-Operative Pain


10/19/2005 5:09:32 PM

NEW YORK--(BUSINESS WIRE)--July 12, 2005--Intrac, Inc. (OTC BB: ITRD.OB) and its wholly-owned subsidiary Innovative Drug Delivery Systems (IDDS) announced today that a pivotal European Phase II/III study of Dyloject(TM) (diclofenac sodium injection) met its primary endpoint of superior pain relief over 4 hours compared to placebo and therapeutic non-inferiority to Voltarol(R). According to Dr Daniel Carr, chief executive officer and chief medical officer, IDDS: "For years clinicians have pursued ways to boost pain relief and reduce the dose of morphine needed to control acute, moderate-to-severe pain. Diclofenac has proven safety and efficacy, but until now there has been no way to give it as a single intravenous dose to patients unable to swallow tablets after operations or trauma. Dyloject(TM) -- like IDDS's other products candidates - offers a simple, safe, cost-effective answer to complex analgesic questions."

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->